Gastric cancer with concurrent pancreatic schwannoma: A case report

Mateus Barradas Ribeiro, Emerson Shigueaki Abe, André Kondo, Adriana Vaz Safatle-Ribeiro, Marina Alessandra Pereira, Bruno Zilberstein, Ulysses Ribeiro Jr

Specialty type: Gastroenterology and hepatology
Provenance and peer review: Invited article; Externally peer reviewed.
Peer-review model: Single blind
Peer-review report’s scientific quality classification
Grade A (Excellent): A
Grade B (Very good): 0
Grade C (Good): 0
Grade D (Fair): D
Grade E (Poor): 0
P-Reviewer: De Raffele E, Italy; Wang YJ, China

Received: November 25, 2021
Peer-review started: November 25, 2021
First decision: January 12, 2022
Revised: January 23, 2022
Accepted: March 26, 2022
Article in press: March 26, 2022
Published online: May 22, 2022

Abstract

BACKGROUND
The differential diagnosis of abdominal masses is somewhat troublesome, especially when there is a malignancy to be evaluated. We report herein a unique case of gastric adenocarcinoma concurrent with a pancreatic schwannoma. Correct assessment of intraoperative findings is essential for adequate tumor staging and to decide the proper management of a concurrent pancreatic lesion.

CASE SUMMARY
Computed tomography scan performed for gastric cancer staging revealed a solid and cystic pancreatic mass that had no signs of local invasiveness. Surgical resection of the pancreas was decided preoperatively since a radical approach of the gastric tumor could be performed. There were no signs of distant metastases, and the large pancreatic mass was in contact with the posterior gastric wall. Histopathological study revealed a pancreatic schwannoma, which is an uncommon neoplasm that arises from Schwann cells around peripheral nerves.

CONCLUSION
Therefore, pancreatic masses deserve special attention regarding the differential diagnosis in patients with gastric cancer. The presence of a large pancreatic mass should not preclude the potentially curative intent of the gastric cancer treatment.

Key Words: Stomach neoplasms; Gastric adenocarcinoma; Schwannoma; Pancreas; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: We display here the first case of synchronous gastric cancer and pancreatic schwannoma, highlighting the relevance of the differential diagnosis in approaching pancreatic masses in the context of staging gastric neoplasm. Correct intraoperative staging was essential in treatment decision-making.

Citation: Ribeiro MB, Abe ES, Kondo A, Safatle-Ribeiro AV, Pereira MA, Zilberstein B, Ribeiro Jr U. Gastric cancer with concurrent pancreatic schwannoma: A case report. World J Gastrointest Pathophysiol 2022; 13(3): 107-113
URL: https://www.wjgnet.com/2150-5330/full/v13/i3/107.htm
DOI: https://dx.doi.org/10.4291/wjgp.v13.i3.107

INTRODUCTION

Accurate staging is essential in gastric cancer treatment decision-making, and any lymph nodes or masses observed in staging assessment should be investigated[1]. Schwannomas, also referred to as neurilemmomas, are rare neoplasms that arise from Schwann cells around peripheral nerves, usually epineurium of either autonomic sympathetic or parasympathetic fibers[2,3]. Pancreatic locations are unusual, with about 70 cases reported in the last 40 years, and most of them are benign. However, malignancy can be found in up to 15% of cases, especially in lesions greater than 6 cm[3-5]. Schwannomas are usually well-encapsulated firm masses, and two-thirds may undergo degenerative changes, which can be cystic formation, calcification, and hemorrhage, among others[2,6]. Due to these alterations, they can mimic cystic pancreatic lesions or metastasis of a different primary site tumor in radiologic investigation, including gastric cancer.

CASE PRESENTATION

Chief complaints
A 73-year-old woman presented with epigastric pain and weight loss.

History of present illness
She had a history of non-insulin-dependent diabetes mellitus, arterial hypertension, and elevated cholesterol level.

History of past illness
She did not report a history of other previous illnesses.

Personal and family history
She was unaware of a family history of cancer.

Physical examination
Abdominal examination did not detect any marked change.

Laboratory examinations
All laboratory data were normal, including hemoglobin of 12.2 g/dL. Serum amylase was 50 U/mL, serum CEA was 1.3 ng/mL, and CA19-9 was 12.7 U/mL.

Imaging examinations
Upper gastrointestinal endoscopy revealed an ulcerated and infiltrative (Borrmann III) lesion measuring 4 cm in the lesser curvature extending to the posterior wall of the antrum and body region. Biopsy revealed a moderately differentiated adenocarcinoma. Preoperative evaluation using computed tomography (CT) scan showed a well-defined 8 cm × 5 cm solid and cystic tumor in the body and tail of the pancreas in close contact to the posterior wall of the gastric body. No sign of infiltration in the surrounding tissue was detected. No liver mass, peripancreatic lymph node swelling, or free peritoneal fluid was detected (Figure 1).
Figure 1  Computed tomography scan showing solid and cystic tumor in the body and tail of the pancreas (pancreatic schwannoma).

MULTIDISCIPLINARY EXPERT CONSULTATION

Laparotomy disclosed a localized gastric tumor in the body and a distinct solid, well-encapsulated tumor at the body of the pancreas without signs of inflammation or neoplastic infiltration. However, the lesion was in close contact to the posterior gastric wall (Figures 2 and 3). Due to the locoregional infiltration of the gastric tumor, absence of distant metastases, and proximity to a large pancreatic lesion, a total gastrectomy with D2 lymph node dissection plus distal pancreatectomy and splenectomy was performed. The final gastric cancer stage was pT2N0, with 0/73 lymph nodes examined (Figure 4). The cut surface of the excised 8 cm pancreatic tumor was pale yellow with hemorrhage foci. On microscopic examination, the lesion showed spindle cells with Antoni A and B patterns and was strongly positive for S100 protein (Figure 5).

FINAL DIAGNOSIS

Gastric adenocarcinoma and concurrent pancreatic schwannoma.

TREATMENT

Total gastrectomy with D2 lymph node dissection, plus distal pancreatectomy and splenectomy.

OUTCOME AND FOLLOW-UP

The patient recovered without any complication, and she was discharged after 12 d. After 44 mo of follow-up, the patient has no evidence of recurrence.

DISCUSSION

In this case report, the patient presented unspecific symptoms including epigastric pain and weight loss. Therefore, it was not possible to define if these symptoms were related to the gastric cancer or if it was a symptomatic case of pancreatic schwannoma. Pancreatic schwannomas appear to be indolent, corroborating its benign nature, and around one-third of the pancreatic schwannomas are asymptomatic. Abdominal pain is the most displayed symptom, ranging from 30% to 57% of patients. Other symptoms are reported less frequently, such as back pain, jaundice, anorexia, vomiting, weight loss, anemia, abdominal mass, and gastrointestinal bleeding[7,8].

CT scan performed for gastric cancer staging showed a solid and cystic pancreatic mass, and it was necessary to make differential diagnosis with a primary pancreatic neoplasm or metastases from the gastric tumor. CT scan may be beneficial in pancreatic schwannoma initial evaluation, and most of them revealed low density or cystic masses, as presented in this case[9,10]. Moreover, magnetic resonance imaging appears to be more helpful in characterizing schwannomas by their typical encapsulation, hypointensity on T1-weighted images, and hyperintensity on T2-weighted images[11,12]. These characteristics are typical radiological features of Antoni A areas, suggesting that these should be classified as
solid hypervascularized tumors of the pancreas. Meanwhile, type Antoni B tumor areas are characterized by a significant cystic component, in which differential diagnosis must be made from a large amount of pancreatic cystic neoplasms\[9,12\]. Fluorodeoxyglucose-positron emission tomography-CT usually demonstrates a hypermetabolic appearance\[8,9\]. Complementary magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography-CT were not performed in this patient but would be helpful in better characterizing morphological tumoral features.

Endoscopic ultrasound-guided fine needle aspiration may be useful, but this method remains controversial due to high false-negative rate. In two reviews, only 44% and 50% of patients were correctly diagnosed with pancreatic schwannoma\[4,8\].

Intraoperative analysis is also a helpful tool in diagnosis, especially to ensure negative margins and correct resection of pancreatic neoplasms, as demonstrated in this case. One review showed that 47% of pancreatic schwannomas were correctly diagnosed, and 33% were reported as benign\[8\], showing that the intraoperative assessment of these tumors may aid the decision making in these cases.

Surgical treatment includes Whipple procedure (pancreaticoduodenectomy) or distal pancreatectomy with or without splenectomy, either because a definite diagnosis was not made pre- or intraoperatively or due to large tumor size\[13,14\] (Table 1). Enucleation should be considered a surgical option when preoperative histopathology confirms the diagnosis. However, a tumor size larger than 6.0 cm, vascular encasement, or visceral invasion should elicit suspicion of malignant transformation, and a more radical approach should be chosen\[4\].

Gastrectomy with D2 lymph node dissection is a gold standard treatment considering the gastric neoplasm; however due to the pancreatic tumor size and the proximity to the posterior gastric wall harboring the tumor, it was decided to perform a partial pancreatectomy with splenectomy in addition.
Table 1 Summary of literature review on pancreatic schwannoma surgical management

| Ref.                | Type of study             | Number of patients | Moment of diagnosis | Surgery performed                        | Size (cm)       | Mean size/range (cm) | Types of pancreatoduodenectomy, % | Enucleation | Surgical resection otherwise non-specified, % | Malignancy, % |
|---------------------|---------------------------|--------------------|---------------------|-----------------------------------------|----------------|---------------------|-----------------------------------|-------------|-----------------------------------------------|----------------|
| Paranjape et al.    | Case report and review    | 40                 | Postoperative       | Enucleation                            | 3.5            | 8.79               | 27 (67.5)                        | 4 (10.0)    | 5 (12.5)                                      | 5 (12.5)       |
| Ma et al.           | Case report and review    | 68                 | Postoperative       | Whipple pancreaticoduodenectomy        | 6 × 5          | 6.1 ± 5.7 (1-33)   | 40 (59.0)                        | 8 (12.0)    | 14 (21.0)                                     | 8 (12.0)       |
| Su et al.           | Case report and review    | 65                 | Intraoperative      | Central pancreatectomy                 | 1.6 × 1.1 × 1.1| 5.83 ± 4.59 (1-20)| 40 (61.5)                        | 9 (13.8)    | 13 (20.0)                                     | 5 (7.7)        |
| Gupta et al.        | Case report and review    | 37                 | Postoperative       | Whipple pancreaticoduodenectomy        | 7.9 × 8.3      | -                  | 19 (51.3)                        | 6 (16.2)    | 9 (24.3)                                      | -              |
| Moriya et al.       | Case report and review    | 47                 | Intraoperative      | Enucleation                            | 4 × 4 × 3      | 6.2 ± 5.1 (1-20)   | 25 (53.0)                        | 7 (15.0)    | 12 (26.0)                                     | 5 (11.0)       |
| Zhang et al.        | Case report and review    | 75                 | Postoperative       | Central pancreatectomy                 | 2.8 and 4.0   | 5.5 ± 5.0 (1.0-30.0)| 45 (60.0)                        | 11 (15.0)   | 14 (19.0)                                     | 4 (5.0)        |
| Watanabe et al.     | Case report               | 1                  | Postoperative       | Subtotal stomach-preserving pancreatiocoduodenectomy | 5.4 × 5.4 | -                  | -                                | -           | -                                             | -              |
| Wang et al.         | Case report               | 1                  | Postoperative       | Distal pancreatectomy with splenectomy | 2.0 × 2.0 × 1.8| -                  | -                                | -           | -                                             | -              |
| Shi et al.          | Case series and systematic review | 6 | Postoperative | Pancreatoduodenectomy 5 (83%) and distal pancreatectomy 1 (17%) | 3.7 (range 2.0-6.4) | 4.3 ± 2.2 (1.4-10) | -                                | -           | -                                             | -              |
| Kimura et al.       | Case report               | 1                  | Postoperative       | Distal pancreatectomy with splenectomy | 1.1 × 0.8     | -                  | -                                | -           | -                                             | -              |

Microscopically, schwannomas are divided in two main subareas: Antoni A areas, displaying an organized hypercellular component, characterized by closely packed spindle cells with occasional nuclear palisading; and Antoni B areas, featuring a hypocellular component with loose myxoid stroma, often with degenerative changes\[^{4,7}\]. Immunohistochemistry is crucial to the differential diagnosis since immunostaining is strongly positive for S-100 protein, vimentin, and CD56 and negative for cytokeratin AE1/AE3, desmin, smooth muscle myosin, CD34, and CD117\[^{4,7,15}\]. In this case, diagnosis was confirmed by the presence of these typical findings in pathology: Antoni A and B areas as well as immunohistochemistry with strong S-100 (+) staining.
Pancreatic schwannomas usually have good prognosis, showing no rates of recurrence over a mean follow-up of 19 mo[4,8].

CONCLUSION
Therefore, we present the first case of synchronous gastric cancer and pancreatic schwannoma reported in the literature. Intraoperative staging examination was decisive in the adequate management of this patient. The presence of a large pancreatic mass should not preclude the potentially curative intent of the gastric cancer treatment.

FOOTNOTES

Author contributions: Ribeiro MB contributed to the study design and drafting of the manuscript; Abe ES, Kondo A, and Safatle-Ribeiro AV contributed to data retrieval and manuscript review; Pereira MA and Zilberstein B contributed to manuscript review; Ribeiro Jr U conceived the study and contributed to critical analysis and manuscript review.

Informed consent statement: Informed consent was waived by the local Ethics Committee because of the retrospective nature of the study.

Conflict-of-interest statement: The authors declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Brazil

ORCID number: Mateus Barradas Ribeiro 0000-0001-8702-0079; Emerson Shigueaki Abe 0000-0001-6054-5705; André Kondo 0000-0003-4842-1363; Adriana Vaz Safatle-Ribeiro 0000-0001-7686-8859; Marina Alessandra Pereira 0000-0002-6865-0988; Bruno Zilberstein 0000-0002-1809-8558; Ulysses Ribeiro Jr 0000-0003-1711-7347.

S-Editor: Liu JH
L-Editor: Filipodia
P-Editor: Liu JH

REFERENCES

1. Rahman MFKP, Pereira MA, Yagi OK, Dias AR, Charruf AZ, Oliveira RJ, Zaidan EP, Zilberstein B, Ribeiro-Júnior U, Cececcolo I. Surgical treatment of gastric cancer: a 10-year experience in a high-volume university hospital. Clinics (Sao Paulo) 2018; 73: e543 [PMID: 30540120 DOI: 10.6061/clinics/2018/e543]

2. Skovronsksy DM, Oberholzer JC. Pathologic classification of peripheral nerve tumors. Neurosurg Clin N Am 2004; 15: 157-166 [PMID: 15177315 DOI: 10.1016/j.nec.2004.02.005]

3. Paranjape C, Johnson SR, Khwaja K, Goldman H, Kruskal JB, Hanto DW. Clinical characteristics, treatment, and outcome of pancreatic Schwannomas. J Gastrointest Surg 2004; 8: 706-712 [PMID: 15558332 DOI: 10.1016/j.gassur.2004.05.010]

4. Ma Y, Shen B, Jia Y, Luo Y, Tian Y, Dong Z, Chen W, Li ZP, Feng ST. Pancreatic schwannoma: a case report and an updated 40-year review of the literature yielding 68 cases. BMC Cancer 2017; 17: 853 [PMID: 29241452 DOI: 10.1186/s12885-017-3856-6]

5. Xu SY, Sun K, Owusu-Ansah KG, Xie HY, Zhou L, Zheng SS, Wang WL. Central pancreatectomy for pancreatic schwannoma: A case report and literature review. World J Gastroentrol 2016; 22: 8439-8446 [PMID: 27729750 DOI: 10.3748/wjg.v22.i37.8439]

6. Gupta A, Subbas G, Mittal VK, Jacobs MJ. Pancreatic schwannoma: literature review. J Surg Educ 2009; 66: 168-173 [PMID: 19712917 DOI: 10.1016/j.jsurg.2008.12.001]

7. Moriya T, Kimura W, Hirai I, Takeshita A, Tetzuka K, Watanabe T, Mizutani M, Fuse A. Pancreatic schwannoma: Case report and an updated 30-year review of the literature yielding 47 cases. World J Gastroenterol 2012; 18: 1538-1544 [PMID: 22590987 DOI: 10.3748/wjg.v18.i13.1538]

8. Zhang X, Siegelman ES, Lee MK 4th, Tondon R. Pancreatic schwannoma, an extremely rare and challenging entity: Report of two cases and review of literature. Pancreatology 2019; 19: 729-737 [PMID: 31157797 DOI: 10.1016/j.pan.2019.05.460]

9. Watanabe T, Araki K, Ishii N, Igarashi T, Watanabe A, Kubo N, Kuvano H, Shirabe K. A Surgically Resected Pancreatic Schwannoma with Obstructive Jaundice with Special Reference to Differential Diagnosis from Other Cystic Lesions in the Pancreas. Case Rep Gastroenterol 2018; 12: 85-91 [PMID: 29606941 DOI: 10.1159/000485555]

10. Yu RS, Sun JZ. Pancreatic schwannoma: CT findings. Abdom Imaging 2006; 31: 103-105 [PMID: 16132429 DOI: 10.1007/s00261-005-0345-1]

11. Wang S, Xing C, Wu H, Dai M, Zhao Y. Pancreatic schwannoma mimicking pancreatic cystadenoma: A case report and literature review of the imaging features. Medicine (Baltimore) 2019; 98: e16095 [PMID: 31192973 DOI: 10.1097/MD.0000000000016095]

12. Novellas S, Chevallier P, Saint Paul MC, Gugenheim J, Bruneton JN. MRI features of a pancreatic schwannoma. Clin Imaging 2005; 29: 433-436 [PMID: 16274899 DOI: 10.1016/j.clinimag.2005.04.017]

13. Shi Z, Cao D, Zhuang Q, You R, Li X, Li Z, Li Y, Huang X. MR imaging features of pancreatic schwannoma: a Chinese case series and a systematic review of 25 cases. Cancer Imaging 2021; 21: 23 [PMID: 33588954 DOI: 10.1186/s40644-021-00390-x]

14. Kimura K, Adachi E, Toyohara A, Omori S, Ezaki K, Ihara H, Higashi T, Ohgaki K, Ito S, Maehara S, Nakamura T, Fushimi F, Maehara Y. Schwannoma mimicking pancreatic carcinoma: A case report. World J Clin Cases 2021; 9: 4453-4459 [PMID: 34141813 DOI: 10.12998/wjcc.v9.i17.4453]

15. Weiss SW, Langloss IM, Enzinger FM. Value of S-100 protein in the diagnosis of soft tissue tumors with particular reference to benign and malignant Schwann cell tumors. Lab Invest 1983; 49: 299-308 [PMID: 6310227]
